New Amsterdam - Full results from phase 3 trial of new Alzheimer’s drug donanemab just presented at Alzheimer’s Association Int'l Conference (Amsterdam), and published in JAMA. Was found to significantly slow clinical progression of the disease compared to a placebo. Some media links follow. :)

7:57am PDT - July 18th, 2023

Full results from phase 3 trial of new Alzheimer’s drug donanemab just presented at Alzheimer’s Association Int'l Conference (Amsterdam), and published in JAMA. Was found to significantly slow clinical progression of the disease compared to a placebo. Some media links follow. :)

2 retweets 0 likes -

RadfordLab (@RadfordLab)